金陵药业
(000919)
| 流通市值：45.95亿 | | | 总市值：45.96亿 |
| 流通股本：6.22亿 | | | 总股本：6.22亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,380,142,974.77 | 1,601,071,008.21 | 810,013,922.67 | 3,281,450,554.73 |
| 营业收入 | 2,380,142,974.77 | 1,601,071,008.21 | 810,013,922.67 | 3,281,450,554.73 |
| 二、营业总成本 | 2,318,855,766.79 | 1,565,898,002.66 | 788,644,161.76 | 3,232,853,911.51 |
| 营业成本 | 1,888,611,372.57 | 1,289,905,608.04 | 653,156,391.47 | 2,675,775,027.9 |
| 税金及附加 | 15,752,595.26 | 10,064,279.06 | 4,488,460.33 | 20,920,658.32 |
| 销售费用 | 74,902,085.72 | 41,514,693.21 | 22,006,480.98 | 85,576,755.22 |
| 管理费用 | 271,433,388.73 | 183,261,110.04 | 90,715,196.32 | 361,153,458.4 |
| 研发费用 | 75,136,411.86 | 45,341,568.66 | 21,182,611.02 | 110,692,239.54 |
| 财务费用 | -6,980,087.35 | -4,189,256.35 | -2,904,978.36 | -21,264,227.87 |
| 其中:利息费用 | 3,844,437.9 | 2,574,532.95 | 922,117.21 | 2,195,885.92 |
| 其中:利息收入 | 11,609,053.76 | 7,243,139.14 | 4,451,970.23 | 24,298,098.53 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 10,178,587.88 | 12,013,263.09 | -1,067,815.24 | 14,387,532.64 |
| 加:投资收益 | 13,521,245.87 | 11,824,341.53 | 9,392,399.03 | 39,616,814.17 |
| 资产处置收益 | -42,789.62 | -44,966.62 | -10,436.12 | 21,343,277.64 |
| 资产减值损失(新) | 0 | 0 | 0 | -92,511,196.69 |
| 信用减值损失(新) | -1,812,715.63 | -1,901,062.12 | -1,722,880.19 | -1,051,685.9 |
| 其他收益 | 6,471,274.5 | 3,425,735.47 | 1,567,564.36 | 12,577,850.97 |
| 四、营业利润 | 89,602,810.98 | 60,490,316.9 | 29,528,592.75 | 42,959,236.05 |
| 加:营业外收入 | 829,901.43 | 720,443.13 | 757,290.71 | 2,694,575.71 |
| 减:营业外支出 | 721,568.38 | 221,742.26 | 104,609.9 | 5,647,735.43 |
| 五、利润总额 | 89,711,144.03 | 60,989,017.77 | 30,181,273.56 | 40,006,076.33 |
| 减:所得税费用 | 14,892,864.4 | 10,572,092.45 | 5,006,368.3 | 22,052,043.16 |
| 六、净利润 | 74,818,279.63 | 50,416,925.32 | 25,174,905.26 | 17,954,033.17 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 74,818,279.63 | 50,416,925.32 | 25,174,905.26 | 17,954,033.17 |
| 终止经营净利润 | 0 | 0 | 0 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 68,458,333.52 | 48,333,532.45 | 22,981,989.14 | 40,409,795.74 |
| 少数股东损益 | 6,359,946.11 | 2,083,392.87 | 2,192,916.12 | -22,455,762.57 |
| 扣除非经常损益后的净利润 | 56,644,232.75 | 35,510,166.16 | 20,439,820.65 | 48,922,210.84 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.11 | 0.08 | 0.04 | 0.07 |
| (二)稀释每股收益 | 0.11 | 0.08 | 0.04 | 0.07 |
| 八、其他综合收益 | -75,520.53 | 0 | 0 | -59,087.26 |
| 归属于母公司股东的其他综合收益 | -41,196.45 | 0 | 0 | -14,401.88 |
| 九、综合收益总额 | 74,742,759.1 | 50,416,925.32 | 25,174,905.26 | 17,894,945.91 |
| 归属于母公司股东的综合收益总额 | 68,417,137.07 | 48,333,532.45 | 22,981,989.14 | 40,395,393.86 |
| 归属于少数股东的综合收益总额 | 6,325,622.03 | 2,083,392.87 | 2,192,916.12 | -22,500,447.95 |
| 公告日期 | 2025-10-28 | 2025-08-28 | 2025-04-28 | 2025-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |